Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42

Mamounas E.; Bandos H.; Lembersky B.; Geyer C.; Geyer C. Jr.; Fehrenbacher L.; Graham M.; Paik S.; Swain S.; Wickerham L.; Wolmark N.

首页> 外文期刊>The Breast : >Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42

【24h】

Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42

机译：延长辅助内分泌治疗与芳香酶抑制剂（AI）后辅助治疗后患有激素受体（+）乳腺癌的绝经后妇女的延长辅助内分泌治疗的影响（+）乳腺癌（AI）：NRG肿瘤学/ NSABP B-42

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2017年第2017期|共2页
作者
Mamounas E.; Bandos H.; Lembersky B.; Geyer C.; Geyer C. Jr.; Fehrenbacher L.; Graham M.; Paik S.; Swain S.; Wickerham L.; Wolmark N.;
展开▼
作者单位

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

NRG Oncol Portfolio Pittsburgh PA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42 [J] . Mamounas E., Bandos H., Lembersky B., The Breast : . 2017,第期

机译：延长辅助内分泌治疗与芳香酶抑制剂（AI）后辅助治疗后患有激素受体（+）乳腺癌的绝经后妇女的延长辅助内分泌治疗的影响（+）乳腺癌（AI）：NRG肿瘤学/ NSABP B-42
2. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 88, 2019) [J] . Mamounas E. P., Bandos H., Lembersky B. C. The lancet oncology . 2019,第1期

机译：在绝经后乳腺癌中使用芳香酶抑制剂的治疗方法（NRG肿瘤学/ NSABP B-42）：随机，双盲，安慰剂控制，第3阶段试验（Vol 20，PG 88,2019）
3. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . Mamounas Eleftherios P., Bandos Hanna, Lembersky Barry C., The lancet oncology . 2019,第1期

机译：在绝经后乳腺癌中使用芳香酶抑制剂的使用后使用Letrozole（NRG肿瘤学/ NSABP B-42）：A随机，双盲，安慰剂控制，第3期试验
4. Bone Density Changes during Adjuvant Aromatase Inhibitor Treatment in Breast Cancer Patients: Single Centre Experience [C] . World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：乳腺癌患者辅助芳香化酶抑制剂治疗期间的骨密度变化：单中心经验。
5. Musculoskeletal symptoms in women on aromatase inhibitors for adjuvant breast cancer therapy. [D] . Olufade, Temitope. 2012

机译：妇女在芳香酶抑制剂上的肌肉骨骼症状可用于辅助性乳腺癌治疗。
6. Interpreting breast international group (BIG) 1-98: a randomized double-blind phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer [O] . Meredith M Regan, Karen N Price, Anita Giobbie-Hurder, 2011

机译：国际乳腺癌解释组织（BIG）1-98：一项随机双盲III期试验比较来曲唑和他莫昔芬作为激素受体阳性的绝经后早期乳腺癌的辅助内分泌治疗方法
7. PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK [O] . Karnon J, Delea TE, Papo NL, 2005

机译：英国早期乳腺癌患者激素受体阳性绝经后妇女初次应用佐剂左来唑对他莫昔芬的PCN32成本效益分析

Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42

著录项

相似文献

相关主题

期刊订阅